A new study, involving scientists from National Institute for Biological Standards and Control (NIBSC), has reported the production of stable poliovirus virus-like particles (VLPs) in plants.
The research, published in the journal Nature Communications, confirms that these plant-made particles are structurally similar to poliovirus and can protect mice from infection as effectively as existing vaccines. As large amounts of live poliovirus are needed to make current vaccines, VLP-based vaccines could provide a safer alternative for vaccine production after polio eradication, said the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) commenting on the development.
VLPs are empty protein shells that ‘mimic’ the virus but lack the genetic material needed for replication. Scientists have suggested poliovirus VLPs as potential vaccine candidates because they can provoke an immune response but aren’t infectious. However, their instability has long been a barrier for their use as vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze